Randomized, Double-Blind Trial of Abatacept for the Treatment of Giant Cell Arteritis

Protocol: A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis

Summary: Patients with GCA who received abatacept in addition to prednisone were less likely to relapse and had more months in remission.

Participating Penn Investigator(s): Dr. Peter Merkel

Journal: Arthritis & Rheumatology, 2017

Disease(s): Giant Cell Arteritis (GCA)